Therapy
The ongoing EVD outbreak has stimulated investigation of several different therapeutic strategies that target specific viral structures and mechanisms of Ebola viruses. Six to eight putative pharmacotherapies or immunologically based treatments have demonstrated promising results in animal studies.
Self-care
FDA approves treatment for ebola virus The U.S. Food and Drug Administration approved Ebanga (Ansuvimab-zykl), a human monoclonal antibody, for the …
Nutrition
What are the treatment options for Ebola?
Does Ebola really make people bleed from their eyes?
What is the best medicine for Ebola virus?
How can you treat Ebola?
What is ZMapp antibody?
NIAID supported the early development and preclinical testing of ZMapp, a "cocktail" of three different monoclonal antibodies. The antibodies bind to three different regions of the glycoprotein of the Ebola virus, inhibiting viral replication. During initial experiments, the antibodies were produced in tobacco plants specifically bioengineered ...
Where is mAb114 from?
mAb114. mAb114 is a monoclonal antibody that was isolated from a survivor of the 1995 Ebola epidemic in the Democratic Republic of the Congo. It was discovered by researchers at NIAID's Vaccine Research Center (VRC), in collaboration with the INRB in the DRC. VRC initially developed and manufactured the mAb114 antibody product, ...
Who makes mAb114?
VRC initially developed and manufactured the mAb114 antibody product, which has now been licensed to Ridgeback Biotherapeutics for advanced development. mAb114 binds to an extremely conserved region on the Ebola virus (specifically the Zaire virus species), thus blocking its interactions with a receptor on human cells.
What is BCX4430?
BCX4430 (also known as galidesivir) developed by BioCryst Pharmaceuticals with support from NIAID, is an investigational small molecule drug with broad spectrum antiviral activity, including against Ebola. BCX4430 has protected animals against infection with Ebola and Marburg viruses, and clinical study of BCX4430 is ongoing
